DrugPatentWatch Database Preview
Patent: 8,722,047
» See Plans and Pricing
Summary for Patent: 8,722,047
| Title: | Humanized anti-HLA-DR antibodies |
| Abstract: | The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab. |
| Inventor(s): | Goldenberg; David M. (Mendham, NJ), Hansen; Hans J. (Picayune, MS), Chang; Chien-Hsing (Downingtown, PA) |
| Assignee: | Immunomedics, Inc. (Morris Plains, NJ) |
| Application Number: | 12/754,140 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,722,047
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck | ELSPAR | asparaginase | VIAL | 101063 | 001 | 1978-01-10 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2025-03-03 | RX | search | |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 001 | 2015-01-23 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2025-03-03 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 002 | 2015-01-23 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2025-03-03 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 003 | 2015-01-23 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2025-03-03 | RX | Orphan | search |
| Nps Pharms Inc | NATPARA | parathyroid hormone | INJECTABLE;INJECTION | 125511 | 004 | 2015-01-23 | Start Trial | Immunomedics, Inc. (Morris Plains, NJ) | 2025-03-03 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,722,047
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 297759 | Start Trial |
| Austria | 417067 | Start Trial |
| Austria | 439860 | Start Trial |
| Austria | 477276 | Start Trial |
| Austria | 500845 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
